Re:Search Institution Members

155 Results for Members

Members

The University of Toronto is a research-intensive university which has been awarded $1.2 billion in research...

Home to world-renowned scientists and labs focused on infectious disease drug discovery, The University of...

Established in 1915, The Walter and Eliza Hall Institute of Medical Research (WEHI) is Australia’s oldest...

The Walter Reed Army Institute of Research (WRAIR) was founded in 1893 as the Army Medical School and today is...

Researchers at AAU’s Aklilu Lemma Institute of Pathobiology undertake a variety of research activities...

The Biomedical Research Institute (BRI) is a nonprofit organization committed to improving global health. BRI...

166 Results for Collaborations

Collaborations

Resistance to current antimalarial drugs is a serious problem. There is a critical need for new medications with novel mechanisms of action. Preliminary data from Dr. Gilbert and others suggested that a certain class of compounds might have antimalarial activity. BVGH connected Dr. Gilbert with scientists at Eisai, who shared proprietary compounds of that class for Dr. Gilbert’s malaria drug discovery program.

A promising series of antimalarial compounds developed in Dr. Van Voorhis’ laboratory, termed bumped kinase inhibitors (BKIs), blocks transmission of malaria parasites from infected humans to mosquitos. BVGH connected Dr. Van Voorhis with scientists at GSK’s Malaria Discovery Performance Unit (DPU) in Tres Cantos, Spain, who re-profiled several BKIs through a battery of kinase/kinome tests to characterize their safety and activity.

Dr. Taylor leaded the Anti-Wolbachia Consortium (A·WOL), whose aim was to develop novel drugs against onchocerciasis and lymphatic filariasis by targeting Wolbachia, the nematodes’ essential endosymbiont. The A·WOL team partnered with AstraZeneca to develop a high-content screening assay for Wolbachia, which was used in screening 1.3 million compounds from AstraZeneca's in-house library that might be re-proposable against onchocerciasis and lymphatic filariasis.

Dr. Wyatt leads the Drug Discovery Unit at the University of Dundee, and was interested in repurposing GSK-3 beta inhibitors for treating kinetoplastid diseases. BVGH connected Dr. Wyatt with AstraZeneca, who shared a targeted library of nine GSK-3 inhibitors with him. Dr. Wyatt tested the inhibitors for activity against T. cruzi, T. brucei, and Leishmania. A compound with interesting activity against L. donovani was identified and AstraZeneca provided 1000 analogues for testing in the University of Dundee assays. Structure release was agreed for 10 of the most promising analogues and any available PK information was provided by AstraZeneca, as well as kinase panel selectivity data. One compound had a promising profile and AstraZeneca provided 200mg of this compound to allow an in vivo efficacy study for visceral leishmaniasis at the University of Dundee. While this compound showed some level of efficacy it also had toxic side effects. Currently this program is progressing at the University of Dundee with its main aim improving the selectivity of the series.

Dr. Liotta had developed nucleoside analogs for a variety of viral diseases and was interested in assessing their promise as new therapies against several DNA and RNA viral pathogens, including dengue, Rift Valley fever, Ebola, influenza, adenovirus, and human herpesviruses. However, he did not have the capacity in his laboratory to do multiple viral family screenings. BVGH connected Dr. Liotta and colleagues with Drs. Cassetti and Tseng, who arranged for NIH-funded contractors to test the compounds in vitro for efficacy against many DNA and RNA viral families. These projects have been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services, under contract numbers: HHSN272201100008I, HHSN272201100013I, HHSN272201100016I, and HHSN272201100019I.

A research team from Caltech designed a low-cost microfluidic qPCR instrument and solicited expert input on tailoring the platform for field diagnosis of tuberculosis. BVGH connected the Caltech investigators with a diagnostics expert at PATH to provide advice regarding multiple aspects of technology development.

170 Results for Assets

Assets

The University of Buea is willing to enter into partnerships for access to its state of the art facilities and expertise in drug screening for onchocerciasis (whole parasite: adult worms, microfilariae and L3; medium throughput). The screens are primarily based on the Onchocerca ochengi model and include a Loa loa microfilariae screening component.
The University of Buea has access to onchocerciasis patients, and can therefore provide to partners a range of biological materials including serum and parasites. We can also undertake epidemiological surveys and field testing. The University of Buea is willing to enter into partnerships for access to its state of the art facilities and expertise in drug screening for onchocerciasis whole parasite: adult worms, microfilariae and L3; medium throughput . The screens are primarily based on the Onchocerca ochengi model and include a Loa loa microfilariae screening component.
The schistosome biological supply center at TBRI makes available to researchers a wide range of schistosome biological material (alive, fresh, frozen and as antigens) for testing antischistosomal compounds. This center supplies biological material to TBRI researchers and to > 20 international research institutes.
Professor Sanaa Botros’ laboratory has the ability to screen anti-schistosomal compounds using in vitro schistosome worm killing and in vivo using a Schistosoma mansoni infected animal model. Also drug evaluation is possible involving different parasitological, immunological and histopathological parameters.
Professor Sanaa Botros’ laboratory is able to conduct efficacy, resistance and bioavailability testing on antischistosomal drugs.
Professor James (Jim) Heath leads a laboratory where one group’s research is in the area of solid-state quantum physics, materials science, and basic surface science, while another group focuses on fundamental biology and translational medicine. On the biology and translational medical side, Heath's group has developed a number of microchip based platforms for highly multiplex analysis of functional proteins from single cells and blood, with specific applications to immune monitoring and tissue analysis, and with a medical focus on oncology. His group also has expertise in creating artificial antibodies that share the high affinity and selectivity of monoclonal antibodies, but maintain the stability of short peptides. They are developing chemistries for targeting these peptides at specific protein epitopes. The superior stability of these capture agents has possible advantages in diagnostic applications for immunoassays, as well as in vivo (imaging and therapeutic) applications. This could potentially be of interest to organizations like PATH and IDRI working on diagnostics especially antibody diagnostics. This might enable the diagnostic to be more stable for developing world applications. So it would be that organizations would know there is a resource or a person with expertise in developing more stable antibodies and could approach to see if there is interest in a collaboration or just sharing of know how.